Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lopinavir/ritonavir monotherapy versus lopinavir/ritonavir plus nucleosides during peginterferon/ribavirin treatment in antiretroviral-naive HIV/HCV coinfected adults
2006-005996-17Phase 3Completed
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- May 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lopinavir + ritonavir, peginterferon alfa-2a and ribavirin in hepatitis C virus infection and human immunodeficiency virus infection (HIV) (2 arms), sponsored by IRCCS Ospedale San Raffaele. Started May 2007; status: completed.
02
Drugs
lopinavir + ritonavirpeginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infectionhuman immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2006-005996-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005996-17.